Targeted NGS analysis to predict recurrence in resected EGFR-mutated lung adenocarcinoma

被引：0
|
作者：
Kim, In Ae [1 ]
Kim, Hee Jung [1 ]
Hur, Jae Young [1 ]
Lee, Seung En [1 ]
Park, Jung Hoon [2 ]
Lee, Song Am [1 ]
Hwang, Jae Jun [1 ]
Kim, Wan Seop [1 ]
Lee, Kye Young [1 ]
机构：
[1] Konkuk Univ, Med Ctr, Seoul, South Korea
[2] Macrogen Inc, Seoul, South Korea
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5896
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5896
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Implications of EGFR expression in MAPK dependency and adaptive immunity status of EGFR-mutated lung adenocarcinoma
    Torasawa, Masahiro
    Yoshida, Tatsuya
    Shiraishi, Kouya
    Yagishita, Shigehiro
    Uehara, Yuji
    Miyakoshi, Jun
    Higashiyama, Ryoko Inaba
    Mochizuki, Akifumi
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Hamamoto, Ryuji
    Yamamoto, Noboru
    Watanabe, Shun-ichi
    Yatabe, Yasushi
    Takahashi, Kazuhisa
    Kohno, Takashi
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] mRNA expression profile specific to micropapillary element in EGFR-mutated lung adenocarcinoma
    Koike, Chihiro
    Matsumura, Mai
    Mitsui, Hideaki
    Kataoka, Toshiaki
    Umeda, Shigeaki
    Tateishi, Yoko
    Suzuki, Takehisa
    Arai, Hiromasa
    Okudela, Koji
    CANCER SCIENCE, 2018, 109 : 1409 - 1409
  • [33] Osimertinib in untreated EGFR-mutated advanced lung adenocarcinoma: real world data
    Almusarhed, Manar
    Rehman, Faisal
    Chen, Ryan
    Ahmed, Samreen
    LUNG CANCER, 2023, 178 : S33 - S33
  • [34] Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report
    Mirallas, Oriol
    Bosch-Schips, Marc
    Pardo, Nuria
    Aubanell, Anton
    Salcedo-Allende, Maria Teresa
    Callejo, Ana
    Iranzo, Patricia
    Tabernero, Josep
    Felip, Enriqueta
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Presence of High-Grade Subtype Predicts Recurrence of Stage I Lung Adenocarcinoma Only in EGFR-Mutated Patients
    Ichinose, J.
    Kondo, Y.
    Ninomiya, H.
    Yamamichi, T.
    Omura, K.
    Hashimoto, K.
    Matsuura, Y.
    Nakao, M.
    Ishikawa, Y.
    Okumura, S.
    Satoh, Y.
    Mun, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S908 - S908
  • [36] TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma
    Gallina, F. T.
    Marinelli, D.
    Taje, R.
    Melis, E.
    Visca, P.
    Buglioni, S.
    Cappuzzo, F.
    Najmeh, S.
    Cools-Lartigue, J.
    Ferri, L.
    Broet, S. Camilleri
    Fiset, P. O.
    Spicer, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S553 - S554
  • [37] High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy
    Lee, S. H.
    Sung, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S932 - S932
  • [38] Outcome of EGFR-Mutated and Non-Mutated Lung Adenocarcinoma Receiving Standard Therapy - A Nepalese Cohort
    Dulal, S.
    Paudel, B.
    Shah, A.
    Neupane, P.
    Acharya, B.
    Chapagain, S.
    Karn, A.
    Shilpakar, R.
    Thapa, R.
    Gautam, B.
    Brustugun, O. T.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S927 - S927
  • [39] Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy
    Chen, Zhuxing
    Liu, Liping
    Zhu, Feng
    Cai, Xiuyu
    Zhao, Yi
    Liang, Peng
    Ou, Limin
    Zhong, Ran
    Yu, Ziwen
    Li, Caichen
    Li, Jianfu
    Xiong, Shan
    Feng, Yi
    Cheng, Bo
    Liang, Hengrui
    Xie, Zhanhong
    Liang, Wenhua
    He, Jianxing
    CANCER MEDICINE, 2022, 11 (16): : 3115 - 3125
  • [40] Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 44 - 54
12345